 Shares of Arrowhead Pharmaceuticals NASDAQ:ARWR decreased 2.49 in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 536.36 over the past year to 0.48, which missed the estimate of 0.12. 